Randomized trial comparing two methods of re-irradiation after salvage surgery in head and neck squamous cell carcinoma: Once daily split-course radiotherapy with concomitant chemotherapy or twice daily radiotherapy with cetuximab.

Détails

ID Serval
serval:BIB_820BB085FC44
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Randomized trial comparing two methods of re-irradiation after salvage surgery in head and neck squamous cell carcinoma: Once daily split-course radiotherapy with concomitant chemotherapy or twice daily radiotherapy with cetuximab.
Périodique
Radiotherapy and oncology
Auteur(s)
Tao Y., Faivre L., Laprie A., Boisselier P., Ferron C., Jung G.M., Racadot S., Gery B., Even C., Breuskin I., Bourhis J., Janot F.
ISSN
1879-0887 (Electronic)
ISSN-L
0167-8140
Statut éditorial
Publié
Date de publication
09/2018
Peer-reviewed
Oui
Volume
128
Numéro
3
Pages
467-471
Langue
anglais
Notes
Publication types: Clinical Trial, Phase II ; Comparative Study ; Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Résumé
A previous randomized trial in recurrent Head and Neck squamous-cell carcinoma (HNSCC) has shown re-irradiation combined with chemotherapy after salvage surgery significantly improved disease-free survival (DFS). The objective of this randomized trial was to compare two methods of re-irradiation in terms of toxicity and survival.
Patients with recurrence/second primary in previously irradiated area were randomly allocated to receive either 60 Gy over 11 weeks with concomitant 5FU - hydroxyurea (VP-arm), or 60 Gy (1.2 Gy twice daily) over 5 weeks with cetuximab (HFR-arm). Primary endpoint was treatment interruption >15 days (acute toxicity).
Twenty-six patients were included in VP-arm and 27 in HFR-arm. One patient in VP-arm experienced >15 days interruption due to toxicity, and none in HFR-arm. In both arms, all patients received at least 60 Gy. In VP-arm, 8/26 patients had chemotherapy delay and/or dose reduction. In HFR-arm, 4/27 patients had <6 cycles cetuximab. There was no significant difference in overall survival (Median OS: 37.4 months vs 21.9 months, p = 0.12). Toxicities and DFS were not different between 2 arms.
Twice daily schedule of re-irradiation of 60 Gy/5 weeks with cetuximab was tolerable and no significant difference in treatment delays occurred between two arms.
Mots-clé
Adult, Aged, Carcinoma, Squamous Cell/mortality, Carcinoma, Squamous Cell/therapy, Cetuximab/administration & dosage, Chemoradiotherapy, Female, Head and Neck Neoplasms/mortality, Head and Neck Neoplasms/therapy, Humans, Male, Middle Aged, Neoplasm Recurrence, Local/therapy, Re-Irradiation/methods, Salvage Therapy, Squamous Cell Carcinoma of Head and Neck, Cetuximab, Head and neck squamous cell carcinoma, Hyperfractionation, Re-irradiation, Recurrent or second primary
Pubmed
Web of science
Création de la notice
24/05/2018 16:58
Dernière modification de la notice
20/08/2019 14:42
Données d'usage